MoonLake Immunotherapeutics Faces Class Action for Alleged Securities Violations

Los Angeles – Investors in MoonLake Immunotherapeutics (NASDAQ: MLTX) are being alerted to a class action lawsuit brought by DJS Law Group LLP, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b‑5. The claim covers shares purchased between March 10, 2024, and September 29, 2025, with a filing deadline of December 15, 2025. According to the complaint, MoonLake made false and misleading statements about the effectiveness of its drug candidate sonelokimab (SLK), claiming advantages over competitors despite Phase 3 trial results that analysts described as “disastrous.” Shareholders who purchased MLTX during the stated period are encouraged to register for case monitoring—without cost or obligation—to explore potential recovery of losses. #MoonLakeImmunotherapeutics #SecuritiesLaw #ClassAction #InvestorRights #SlimScan #GrowthStocks #CANSLIM